Introduction: Cancer end-of-life care and associated racialethnic disparities have been in focus during the last few years due to concerns regarding subjective care variations and poor quality of care. Given the high mortality rate and disease burden of lung cancer, end-of-life care quality is particularly crucial for this disease. This study uses previously validated measures and examines racial-ethnic disparities in lung cancer end-of-life care quality.
Introduction
Lung cancer is the second most common cancer and the leading cause of cancer deaths in the United States. 1 The lack of technology for regular lung cancer screening in the general population results in delayed diagnosis, with more than 60% of the patients being diagnosed at American Joint Committee on Cancer (AJCC) stages III-IV, and only 18% of the patients surviving beyond 5 years after diagnosis. 2, 3 Given the high mortality rate, end-of-life care is crucial for lung cancer.
Cancer end-of-life care has been in focus during the last few years due to concerns regarding aggressive treatment against patient preferences, subjective provider-level care variations, reduced quality of care, and reduced patient quality of life. Poor end-of-life care quality often entails excessive inpatient utilizations, aggressive therapy provisions, and reduced hospice care. Studies have reported that the number of Medicare cancer patients receiving intensive care during end-oflife and deaths in acute care settings have increased over the years. [4] [5] [6] [7] Although the increase in aggressive end-of-life care has coincided with an increase in the use of hospice care, hospice care is often initiated 1 to 3 days before death, thereby undermining its utility. 5, 8 End-oflife care is also an expensive phase of cancer care, and most of the spending during end-of-life is due to hospitalizations. 4, 9 Given that the national expenditure on cancer is expected to increase to $173 billion in 2020, discussions about reducing inappropriate utilizations, and improving care quality have become imperative. 10 Concerns regarding poor end-of-life cancer care quality have sparked numerous Institute of Medicine and American Society of Clinical Oncology reports aimed at standardizing end-of-life cancer care, reducing aggressive care, and ensuring timely hospice initiation. [11] [12] [13] In addition to these initiatives, public agencies and research groups have created and validated quality of care indictors to identify areas of concern in end-of-life cancer care, document subjective regional and provider-level variations in care, and examine changes in these indicators over time. The most commonly used quality indicators for administrative/claims data have been developed and validated by Earle et al. 14 Although subjective variations in end-of-life cancer care provision have received considerable attention, racial-ethnic disparity in end-of-life cancer care needs further emphasis. Lung cancer mortality and subsequently the burden of end-of-life lung cancer care is higher among minorities due to higher lung cancer risk, later stage at diagnosis, and higher likelihoods of delayed and inappropriate treatment administration. 2, 15, 16 In addition, minorities are often subjected to poor quality and more aggressive care near death. 5, 8, 17 Racial-ethnic minorities are more likely to receive care in the emergency room (ER), intensive care unit (ICU), and inpatient facility, and less likely to receive hospice care during end-of-life. 8, 18 Given these findings, it becomes important to understand the effect of race-ethnicity on the type and quality of end-of-life care for all lung cancer patients, identify areas of concern, and subsequently develop guidelines to address these concerns.
Only six studies have examined racial-ethnic disparities in end-of-life cancer care quality using existing validated quality indicators, and none of these studies focused on lung cancer of all AJCC stages. 5, 6, 8, 17, 19, 20 The current study for the first time focused on racial-ethnic disparities in end-of-life care quality using a nationally representative data of lung cancer patients. 21 The study used seven variables, which have already been validated for use in administrative datasets, to assess end-of-life care quality. 14, 22, 23 These variables can be grouped into three themes: (1) potentially preventable medical encounters in the last month of life, (2) delayed hospice referral during end-of-life, and (3) aggressive chemotherapy provision in the last month of life.
Materials and Methods

Study Data and Sample Characteristics
This study uses the Surveillance Epidemiology and End Result (SEER) program data containing newly diagnosed lung cancer patients between 1992 and 2011 linked to Medicare claims from 1991 to 2013. SEER represents nearly 25% of the U.S. population, and includes patient sociodemographic, tumor and treatment characteristics, and vital statistics data. Medicare provides health insurance to almost 97% of people 65 years and older in the United States. 21 Consequently, the SEER-Medicare linked files longitudinally track utilization information for nearly 93% of SEER patients 65 years and older. 21 This study included patients 66 years and older, who were diagnosed for the first time with AJCC stage I-IV lung cancer between 1992 and 2011, and who died on or before December 31, 2013. Only patients 66 years and older were included to allow for the assessment of prediagnostic comorbidity from 1 year of Medicare claims before diagnosis. Death on or before December 31, 2013, was required to ensure availability of all end-of-life Medicare claims data. To ensure the availability of complete claims during the study period, all patients were required to be continuously enrolled in Medicare parts A and B, and not enrolled in a Health Maintenance Organization, for 12 months before (comorbidity assessment period) and 6 months after diagnosis (treatment variable measurement period), and 1 month before death (dependent variable measurement period). However, those surviving for less than 7 months after diagnosis were only required to meet the enrollment criteria from diagnosis until death (in addition to meeting the enrollment criteria for 12 months before diagnosis). Patients diagnosed at the time of death or during autopsy, patients who developed another primary malignant cancer after being diagnosed with the first lung cancer, and patients with disabilities and/or end-stage renal disease (ESRD) were excluded. Although it would have been interesting to examine the effect of ESRD on treatment decisions during end-of-life, the study sample had less than 1% ESRD patients. The study did not have sufficient power to tease out the effect of ESRD on end-of-life care, thereby leading to the exclusion of ESRD patients to create a relatively homogenous study sample. Patients were excluded if the date of death reported in SEER and Medicare differed by more than 2 months.
Patients were divided into two cohorts, NSCLC and SCLC, and analyzed separately because of the considerable therapeutic and prognostic differences between the two histological categories. Patients with NSCLC were identified using the International Classification of Diseases for Oncology, third edition histology codes 8010, 8011-8015, 8016-8040, 8046, 8050-8084, 8140-8384, 8440-8490, and 8560-8576; and patients with SCLC were identified using codes 8002 and 8041-8045. 24 
Dependent Variables
Quality of end-of-life care was measured using seven variables developed and validated by Earle et al. and endorsed by the Agency for Healthcare Research and Quality (AHRQ) and the National Institutes of Health. 14, 22 We classified the seven variables into the three themes mentioned above, as suggested in a previous publication. 23 The first theme of potentially preventable medical encounters examined the utilization of preventable acute care services, such as hospitalization, ER and ICU, and also examined deaths in an acute care setting during the end-of-life. The theme comprised of four variables: (1) more than one ER visit during the last 30 days of life, (2) more than one hospital stay during the last 30 days of life, (3) at least one ICU stay during the last 30 days of life, and (4) death in an acute care setting. The second theme of delayed hospice referral captured inappropriate use of hospice care and was measured using one variable: (5) initiation of hospice care during the last 3 days of life. The third theme of aggressive chemotherapy provision focused on a cancer-specific therapy and was measured using 2 variables: (6) starting a new chemotherapy regimen 30 days before death and (7) receiving any chemotherapy in the last 14 days of life. Capturing the start of a new chemotherapy regimen (for the sixth dependent variable above) required identification of new chemotherapy lines, and an algorithm used by Davis et al. was used to identify chemotherapy lines. 25 Other cancer-specific therapies, such as provision of radiation therapy during end-of-life, were not examined. This is because the study examined only those variables which were validated in the literature for use in administrative/claims data, and were subsequently reviewed and summarized by AHRQ. 22 A composite measure of "aggressiveness of care" was created, which captured the occurrence of any of the "potentially preventable medical encounter" or "aggressive chemotherapy provision" events during the patient's end-of-life care, as defined by Earle et al. 5 Earle et al. 5 found that the six variables captured under the themes of "potentially preventable medical encounters" and "aggressive chemotherapy provision" were highly positively correlated with each other based on the Spearman rank testing. Hence, this study used the composite measure of "aggressiveness of care" to examine if the overall management of lung cancer was more aggressive among certain racial-ethnic groups in the study.
Independent variables
Race-ethnicity was the main independent variable of interest and was categorized as non-Hispanic (NH) white, NH black, Hispanic, and others. NH white was the reference category in all regression analyses. In addition to race-ethnicity, other patient sociodemographic, clinical, tumor and treatment characteristics, and year of diagnosis were also controlled for in all regression analyses (Table 1) . Patient sociodemographic characteristics included age at diagnosis (measured in years), gender, marital status, income, education, urban-rural area of residence, and SEER region of residence. The SEER regions of Atlanta, greater Georgia, and rural Georgia, were combined to form "Georgia." Similarly, the SEER regions of San Francisco, San Jose, Los Angeles and Greater California were combined to form "California." Since income and education information are not available at the person-level, median household income (measured in dollars) and education at the census tract level were used, as validated by past studies. 26, 27 For cases where census tract data were missing the same information was obtained from the ZIP code level. Education was defined as proportion of college-educated individuals in the census tract or ZIP code of residence. The square of age (in addition to the continuous measure of age in years) was added and median household income was log-transformed to improve the model fit and statistical significance of these variables.
Patient clinical characteristics included history of previous cancers and modified Charlson comorbidity index (developed using claims incurred during the year before diagnosis). Tumor characteristics at diagnosis included stage, histology, tumor grade, tumor size, and lymph node status. Moderately differentiated or welldifferentiated tumor grades were categorized as low grade, and undifferentiated or poorly differentiated grades were categorized as high grade.
Treatment characteristics included time to treatment initiation after diagnosis, and the receipt of surgery, lymph node dissection, chemotherapy, and radiation therapy within the first 6 months after 
Statistical Analyses and Other Considerations
The regression analyses in this study required consistent measurement of the dependent variables from claims filed during the last month of life for all patients. In addition, the study required measurement of receipt of surgery, lymph node dissection, chemotherapy, and radiation therapy during the first 6 months after diagnosis. To ensure that the patients being analyzed had equal lengths of time to measure the variables, this study further divided the NSCLC and SCLC cohorts into three subgroups (thereby leading to the creation of six analytical subgroups): (1) those surviving for less than 1-month after diagnosis, (2) those surviving for 1 to 7 months after diagnosis, and (3) those surviving for more than 7 months after diagnosis. Patients surviving for less than 1 month were not included in any regression analyses but were descriptively studied because these patients do not have sufficient survival after diagnosis to measure the dependent variables consistently.
To reduce endogeneity, this study ensured that: (1) The independent variables measuring receipt of any treatment and the dependent variables are captured from non-overlapping periods; and (2) The independent variables are measured in a period before the period used for dependent variable measurement. Subgroups described in 2 and 3 above were analyzed separately using multivariable regression analyses, and receipt of surgery, lymph node dissection, chemotherapy, and radiation therapy were only controlled for, while analyzing patients who survived for more than 7 months after diagnosis. Patients who have 1 to 7 months of survival have an unequal period after diagnosis to capture the receipt of any treatment, after excluding the claims from the last month of life for the measurement of the dependent variables. Hence, receipt of different treatments was not measured among patients surviving 1 to 7 months to ensure consistency of variable measurement within subgroups while performing a multivariable regression analysis.
Descriptive analyses using chi-square tests were performed to examine the bivariate associations between race-ethnicity and quality of end-of-life care indicators within each of the six subgroups described above. Multivariable logistic regressions were performed, with end-of-life care quality variables as the dependent variables for subgroups 2 and 3 described above, controlling for race-ethnicity and all other independent variables. All analyses were conducted using Stata version 13 (StataCorp LLC, College Station, Texas), and statistical tests with a p <.05 were considered significant.
Results
The results of the descriptive analyses are reported in Table 1 . There were 154,498 patients with NSCLC and 27,834 with SCLC who died on or before December 31, 2013, in the study. Eight-four percent of the NSCLC and 88% of the SCLC patients were NH white. The average age of both cohorts was 75 to 76 years. NSCLC patients had a slightly higher proportion of men compared to SCLC patients (NSCLC males -55%; SCLC males -49%). Most of the NSCLC and SCLC patients were married (51%). The patients in both cohorts lived in neighborhoods that had an average median income of $46,000 to $47,000, had approximately 51% to 52% of adults with college education or more, and were predominantly urban (98%). Almost a quarter of the patients in both cohorts lived in California.
A majority of the patients in both cohorts did not have a previous cancer diagnosis (84% to 87%) and had a modified Charlson comorbidity index of 1 or less (71%) ( Table 1) . Adenocarcinomas formed the largest histologic group among the NSCLC patients (42%). SCLC had a considerably higher proportion of patients with advanced cancer stage at diagnosis, with 61% of SCLC patients being diagnosed at AJCC stage IV as compared with 45% of NSCLC patients being diagnosed at stage IV. Consequently, a higher proportion of SCLC patients had tumors with higher grades and larger sizes (among the patients with known tumor size), and had a higher percentage of lymph node-positive status at diagnosis. A higher percentage of SCLC patients started treatment within 2 months of diagnosis as compared with NSCLC patients (70% SCLC versus 62% NSCLC). As expected, due to the relatively lower stage at diagnosis among NSCLC patients, a higher proportion of NSCLC patients received surgery and lymph node dissection, and a lower proportion received chemotherapy as compared with SCLC patients.
Most NSCLC and SCLC patients died after the first month but before completing 7 months after diagnosis (49%). One-year survival improved over time for lung cancer patients from 33% to 45% (results not exhibited in tables). However, this study only included patients who died, and among those patients the proportion dying at or before completing 7 months, and the proportion dying after 7 months following diagnosis, do not change significantly over time. We also examined the distribution of patients surviving for less than a month, 1 to 7 months, and more than 7 months by race-ethnicity and did not find any racial-ethnic differences. Table 2 shows racial-ethnic differences in the percentage of lung cancer patients receiving poor quality end-of-life care. Among patients surviving less than 1 month after diagnosis, statistically significant racialethnic differences in poor quality end-of-life care were minimal. On an average, Hispanics had a higher proportion of more than one ER visit and at least one ICU stay during the last 30 days of life, and a higher proportion of death in an acute care setting as compared with NH whites. A higher proportion of patients surviving less than 1 month after diagnosis received aggressive end-of-life care (>70%), with more than 50% of these patients dying in an acute care setting, as compared with patients who survived for more than a month after diagnosis.
Among patients surviving 1 to 7 months after diagnosis, NH blacks and Hispanics had a higher proportion of preventable medical encounters in the last month of life, as compared with NH whites (Table 2 ). Hospice care initiation during the last 3 days of life was mostly similar among all race-ethnicities among patients surviving 1 to 7 months after diagnosis, with marginally lower rates of delayed hospice referral among NH blacks with NSCLC. Aggressive chemotherapy provision in the last month of life was less common among NH blacks as compared to NH whites in patients surviving 1 to 7 months after diagnosis. Nevertheless, a higher proportion of NH blacks and Hispanics received overall aggressive care near end-of-life, as compared with NH whites, in patients surviving 1 to 7 months after diagnosis. The racial-ethnic differences in quality of end-of-life care for patients surviving more than 7 months after diagnosis were similar to the differences in patients surviving 1 to 7 months. Table 3 provides 32 sets of adjusted odds ratios of receiving poor quality end-of-life care for each raceethnicity category (with NH whites as the comparison group) using multivariable logistic regression analyses. Among both NSCLC and SCLC patients, irrespective of survival duration, NH blacks had 20% to 40% higher odds of more than one ER visit, more than one hospital stay, at least one ICU visit, death in an acute care setting, and overall provision of aggressive care as compared with NH whites. On the other hand, NH blacks had lower odds of hospice care initiation during the last 3 days of life, and lower odds of aggressive chemotherapy provision during the last month of life as compared with NH whites in most subgroups analyzed (except the SCLC patients with more than 7 months of survival after diagnosis).
Among NSCLC patients, Hispanics had higher odds of more than one ER visit, more than one hospital stay, at least one ICU visit, death in an acute care setting, and overall provision of aggressive care as compared with NH whites. Among SCLC patients, only few of the poor quality of care indicators were statistically different between Hispanics and NH whites. Nevertheless, all the statistically significant differences in the SCLC cohorts showed a higher level of poor quality of care among the Hispanics as compared with the NH whites.
Other variables associated with end-of-life care quality in the 32 multivariable logistic regressions performed for Table 3 were also examined (results not shown in tables). Being a woman reduced the odds of having potentially preventable medical encounters, delayed hospice referral, and aggressive chemotherapy provision in the last month of life. Belonging to an area with higher median income and lower percentage of college-educated residents increased the odds of having potentially preventable medical encounters in the last month of life. As expected, having a higher comorbidity index was associated with higher odds of potentially preventable medical encounters in the last month of life. Patients diagnosed with a higher tumor stage had lower odds of potentially preventable medical encounters but higher odds of aggressive chemotherapy provision in the last month of life. Unfortunately, patients diagnosed more recently had higher odds of potentially preventable medical encounters, delayed hospice referral, and aggressive chemotherapy provision in the last month of life, suggesting an increase in the use of aggressive endof-life care in more recent years. The only exception was a reduction in deaths in acute care settings during recent years.
Additional sensitivity analyses for initiation of hospice in the last 3 days were performed in a subsample of patients who had received any hospice in the last 6 months of life. Among these patients, only NH blacks with NSCLC who survived for 7 months were 12% less likely to initiate hospice during the last 3 days of life. None of the other racial-ethnic categories were statistically different. Additional subgroup analyses were also performed for patients with advanced-stage NSCLC (AJCC stage IIIB and IV). The racial-ethnic differences in both survival subgroups of advanced-stage NSCLC were predominantly the same as the NSCLC cohort exhibited in Table 3 . The results of these sensitivity and subgroup analyses are not shown in the tables.
Discussion
This study found considerable racial-ethnic disparities in end-of-life care quality among lung cancer patients. In particular, the study found that the racialethnic minorities (NH blacks and Hispanics) had higher odds of experiencing potentially preventable medical encounters in the last month of life as compared with NH whites. Nevertheless, the odds of delayed hospice referral or aggressive chemotherapy provision were lower in NH blacks as compared with NH whites, with no statistically significant differences in these indicators between NH whites and Hispanics.
Previous studies have reported similar findings with regard to racial-ethnic disparities. Studies found that among cancer patients, racial-ethnic minorities were more likely to have potentially preventable medical encounters, which included higher rates of ER, ICU, and inpatient visits during end-of-life, and higher rates of deaths in acute care settings. 5, 8, 17, 20, 28 Black patients also had an increased risk of experiencing discontinuous stays in nursing homes and multiple hospitalizations in the last 90 days of life, and had higher transfers between facilities in the last 3 days of life. 29 Higher potentially preventable medical encounters in the last month of life among minorities could be a result of several factors. To begin with, higher likelihood of inappropriate care provision among minorities persists during all phases of cancer care. Minorities have lower access to screening, are diagnosed later with a higher disease stage, initiate treatment later, have lower likelihood of receiving stage-appropriate treatment, and have higher rates of disease-specific mortality. 2, 15, 16 The factors causing the disparities in care provision during the early phases of cancer management might also precipitate inappropriate end-of-life care. Some of these previously identified factors are absence of a usual The 32 sets of odds ratios, for the race-ethnicity variable displayed above, required 32 multivariable logistic regressions. All 32 multivariable logistic regression models were adjusted for patient sociodemographic characteristics, patient clinical characteristics, tumor characteristics at diagnosis, time to treatment initiation after diagnosis, and year of diagnosis. In addition to the aforementioned variables, multivariable logistic regression models for patients surviving >7 months were also adjusted for treatment characteristics consisting of receipt of surgery, lymph node dissection, chemotherapy, and radiation therapy. a Significant at p < 0.01. b Significant at p < 0.05. OR ¼ odds ratio; CI ¼ confidence interval; ER ¼ emergency room; NH ¼ non-Hispanic; ICU ¼ intensive care unit.
source of care, lower likelihood of having a medical home, lower family and social support for medical decision-making, lower family and social support to provide regular home-based health care, and geographic barriers to good quality care. [30] [31] [32] [33] In addition, lack of timely and appropriate care at early phases of cancer management could potentially precipitate urgent or intensive inpatient utilizations during end-of-life. 34 Also, provider's preparedness, training and competence in estimating survival, and initiating discussions during end-of-life is critical for end-of-life care quality. 35 Minorities have lower access to good quality providers. 36, 37 In addition, providers are shown to hold implicit biases against racial-ethnic minorities and their ability to understand medical decision-making. 38, 39 These factors can lead to less informed and low quality end-of-life care decisions.
In addition, patient preferences and lack of information could also lead to provision of aggressive end-of-life care. Past studies show that black patients were more likely to choose more treatment during end-of-life, want life-sustaining treatment, and change a "do not resuscitate" preference to "cardiopulmonary resuscitation." 40, 41 In addition, black and Hispanic patients with metastatic cancers were more likely to exhaust personal resources for life-extending treatments. 42 Moreover, blacks and Hispanics had a higher likelihood of misunderstanding advance directives and palliative care, and were consequently less likely to use these. 43, 44 Studies have also shown that spiritual beliefs among black patients have an impact on how they perceive death and make health care decisions. 45, 46 Blacks are more likely to believe in divine intervention, leading to a higher preference for life-sustaining procedures and end-of-life inpatient utilizations.
The lower likelihood of delayed hospice initiation among NH blacks in this study may be a function of an overall lower use of hospice among NH blacks. This is supported by our sensitivity analysis showing no statistically significant differences between most racialethnic categories when the regression of delayed hospice initiation is limited to patients having any hospice initiation during the last 6 months of life. Past studies have shown that black patients were less likely to receive hospice and palliative care during the end-of-life period. 6, 8, 18, 20 Based on previous studies, the most common reasons for low hospice and palliative care use among minorities are: (1) limited access to hospice in minority neighborhoods as compared with white neighbourhoods; 47 (2) reduced supply of opioid analgesics, used as pain medication during palliative care, in minority neighborhoods; 48 (3) lower physician-to-patient ratio in minority neighborhoods, which in turn reduced hospice use; 49 and (4) lack of access to important services and clinical resources to physicians of black patients. 50 Similar to lower hospice care, less aggressive chemotherapy provision during end-of-life among minorities could also be a function of sustained reduced access to systemic therapy during all cancer care phases. Studies show that black patients were less likely to receive stage-appropriate systemic treatment, especially chemotherapy, during all cancer care phases, including end-of-life. 6, 8, 16, 51 Similar to previous studies, this study also found an increase in the use of aggressive end-of-life care in recent years. [4] [5] [6] [7] [8] Although overall hospice care use had increased over time in the study population (results not shown in tables), the corresponding increase in delayed hospice referral and an increase in most potentially preventable medical encounters and aggressive chemotherapy provision demonstrates a worsening quality of end-of-life care that needs to be proactively addressed in the coming years.
This study had few limitations. First, given the nature of the study data, it is difficult to tease out the reasons for racial-ethnic disparities, such as physician attitudes, patient beliefs/preferences, and health care access. Second, the income and education variables controlled for in the analyses were at the level of the census tract, and there is a possibility that individual-level socioeconomic differences may have confounded the racial-ethnic differences reported in the study. 16 Third, the study excluded Health Maintenance Organization-enrollees, and only included patients who were 66 years or older having both Medicare parts A and B enrollment. In the national sample, approximately 10% of lung cancer patients are black, whereas 6% to 8% of lung cancer patients in this study sample are NH black. The age and insurance-based inclusion/exclusion criteria slightly reduced the proportion of NH black patients included in the study, thereby possibly limiting the generalizability of this study.
Nevertheless, the study has considerable strengths which outweigh the limitations. First, the SEER registries are population-based and do not have selection and reporting bias, unlike sampled or surveyed data. 16 Second, SEER data on tumor incidence and characteristics are high quality and valid with 98% case ascertainment. In addition, the linked Medicare claims provide utilization information for 97% of the population age 65 years or older. 21 Third, the end-of-life care quality variables used in the study were validated in an evidence report published by an AHRQ-funded expert panel, and have high sensitivity, specificity, and accuracy. 14, 22 Finally, this is the first study that uses two decades of nationally representative SEER-Medicare data to examine racialethnic disparities in lung cancer end-of-life care.
To summarize, this study found that NH blacks and Hispanics have a higher likelihood of receiving potentially preventable medical encounters in the last month of life. This finding might indicate continued lack of access and care disparity among the minorities during the earlier phases of cancer care, which might precipitate potentially preventable utilizations during end-oflife. The study's findings of lower hospice referral and less aggressive chemotherapy provision during end-oflife among minority populations could also be a result of continued lack of access during all cancer care phases. These findings indicate the need to examine the access of minority populations to appropriately trained providers during all phases of cancer care and their geographic access to hospice care. Interventions might be required to reduce provider-level biases involving racial-ethnic minorities. In addition, future studies establishing the sociopsychological, theological, and economic reasons behind these racial-ethnic disparities are crucial for developing patient-level strategies to address these disparities. Quantitative and qualitative studies using patient survey data are required to identify the beliefs, preferences, and attitudes that contribute to racial-ethnic disparities. Identifying patient-level reasons for racial-ethnic disparities will help develop educational and patient navigation interventions to facilitate appropriate patient-level decision-making during end-of-life.
